Teva announces $3,500,000,000 debt tender offers for notes due 2022-2024

Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) (“teva”) announced today that it has commenced tender offers (the “offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $3,500,000,000 (the “total maximum amount”) of the following series of notes issued by finance subsidiaries of teva and guaranteed by teva: 1.250% senior notes due 2023, isin xs1211040917, issued by teva pharmaceutica
TEVA Ratings Summary
TEVA Quant Ranking